[go: up one dir, main page]

ES2182334T3 - Monohidrato de eprosartan. - Google Patents

Monohidrato de eprosartan.

Info

Publication number
ES2182334T3
ES2182334T3 ES98931693T ES98931693T ES2182334T3 ES 2182334 T3 ES2182334 T3 ES 2182334T3 ES 98931693 T ES98931693 T ES 98931693T ES 98931693 T ES98931693 T ES 98931693T ES 2182334 T3 ES2182334 T3 ES 2182334T3
Authority
ES
Spain
Prior art keywords
monohidrate
eprosartan
compound
thiopheropropionic
carboxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98931693T
Other languages
English (en)
Inventor
Sarma Duddu
Nageswara R Palepu
Gopadi M Venkatesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2182334T3 publication Critical patent/ES2182334T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere al monohidrato de monometanosulfonato del ácido (E)-{al}-[2-N-butil-1-[(4-carboxifenil)metil]-1H-imidazol-5-il]metileno-2-tiofenopropiónico, las composiciones que contienen al compuesto y procedimientos de empleo del compuesto para bloquear a los receptores de angiotensina II y para tratar la hipertensión, e insuficiencia cardiaca e insuficiencia renal.
ES98931693T 1997-06-27 1998-06-26 Monohidrato de eprosartan. Expired - Lifetime ES2182334T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5117097P 1997-06-27 1997-06-27

Publications (1)

Publication Number Publication Date
ES2182334T3 true ES2182334T3 (es) 2003-03-01

Family

ID=21969760

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98931693T Expired - Lifetime ES2182334T3 (es) 1997-06-27 1998-06-26 Monohidrato de eprosartan.

Country Status (7)

Country Link
US (1) US6262102B1 (es)
EP (1) EP0991647B1 (es)
JP (1) JP4475685B2 (es)
CA (1) CA2294515C (es)
DE (1) DE69807695T2 (es)
ES (1) ES2182334T3 (es)
WO (1) WO1999000383A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
NZ514855A (en) 1999-04-28 2004-01-30 Takeda Chemical Industries Ltd Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
RU2423127C2 (ru) * 2005-12-06 2011-07-10 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против роговично-конъюнктивального нарушения
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US8361507B2 (en) * 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2153822A1 (en) 2008-08-13 2010-02-17 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
EP2293781A1 (en) * 2008-04-09 2011-03-16 LEK Pharmaceuticals d.d. Granulation of active pharmaceutical ingredients
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP4316013B2 (ja) * 1996-03-29 2009-08-19 スミスクライン・ビーチャム・コーポレイション エプロサルタン二水和物ならびにその製法および処方

Also Published As

Publication number Publication date
EP0991647B1 (en) 2002-09-04
CA2294515C (en) 2007-08-28
JP4475685B2 (ja) 2010-06-09
CA2294515A1 (en) 1999-01-07
JP2002507213A (ja) 2002-03-05
DE69807695D1 (en) 2002-10-10
EP0991647A1 (en) 2000-04-12
EP0991647A4 (en) 2001-08-16
WO1999000383A1 (en) 1999-01-07
DE69807695T2 (de) 2003-07-31
US6262102B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
AR006439A1 (es) Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
ES2182334T3 (es) Monohidrato de eprosartan.
PE20040468A1 (es) Combinacion de compuestos organicos
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
NO20010062D0 (no) Bifenylsulfonamider som duale angiotensin-endotelin- reseptorantagonister
TR200000782T2 (tr) Resorsinol türevleri.
ES2190976T3 (es) Composiciones de n-clorosulfamato que tienen eficacia antimicrobiana mejorada.
BR9912145A (pt) Formulações bioaperfeiçoadas contendo eprosartan em forma de dosagem sólida oral
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EA200300105A1 (ru) Нестероидные ингибиторы воспалений
EA200300580A1 (ru) Соединения лактама
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
DE69007740D1 (de) Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
BR9811948A (pt) Secretores de hormÈnio do crescimento
DK0492105T3 (da) Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
ATE286885T1 (de) Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
BR0015980A (pt) Agente para profilaxia ou tratamento do glaucoma, e, uso de um antagonista de angiotensina ii
BR9814877A (pt) Formulações de dosagem oral de elevada carga medicamentosa de liberação imediata e modificada e processos para sua fabricação
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
PT1019048E (pt) Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal
ES2152948T3 (es) Derivados de imidazol, triazol y tetrazol.
BR9811926A (pt) Complexo de neutralização de carga de eprosartan arginila e um processo para a sua produção e formulação